| 1. |
|
|
| 2. |
- Andlin-Sobocki, P, et al.
(author)
-
Cost of addiction in Europe
- 2005
-
In: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 28-33
-
Journal article (peer-reviewed)
|
|
| 3. |
- Andlin-Sobocki, P, et al.
(author)
-
Cost of affective disorders in Europe
- 2005
-
In: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 34-38
-
Journal article (peer-reviewed)
|
|
| 4. |
- Andlin-Sobocki, P, et al.
(author)
-
Cost of disorders of the brain in Europe
- 2005
-
In: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 1-
-
Journal article (peer-reviewed)
|
|
| 5. |
- Andlin-Sobocki, P, et al.
(author)
-
Cost of psychotic disorders in Europe
- 2005
-
In: European journal of neurology. - : Wiley. - 1351-5101 .- 1468-1331. ; 1212 Suppl 1, s. 74-77
-
Journal article (peer-reviewed)
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
- Kobelt, Gisela, et al.
(author)
-
The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.
- 2008
-
In: Scandinavian Journal of Rheumatology. - : Informa UK Limited. - 1502-7732 .- 0300-9742. ; 37:1, s. 62-71
-
Journal article (peer-reviewed)abstract
- Objective: To estimate the cost-effectiveness of treating ankylosing spondylitis (AS) with infliximab (Remicade(R)) in Spain for up to 40 years. Methods: A previously published disease model was adapted to the Spanish setting using resource consumption from a cross-sectional burden of an illness study in 601 patients in Spain. Cost-effectiveness estimates were based on a placebo-controlled clinical trial as well as an open clinical study in Spain. In the model, patients with insufficient response to treatment at 12 weeks [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <4 or >/=50% reduction] discontinue treatment. The results are presented in 2005 euros, from societal and health-care payer perspectives. Results: In the societal perspective, infliximab treatment dominates standard treatment in both analyses. In the perspective of the health-care system, with the assumption that, over the long term, functional ability of patients on treatment would decline at half the natural rate, the cost per quality-adjusted life year (QALY) gained was estimated at EUR 22 519 (double-blind trial) and EUR 8866 (open study). Assuming that patients' function on treatment remains stable, the cost-effectiveness ratios are EUR 15 157 and EUR 5307, respectively. Under the most conservative assumption (no effect of treatment on progression), the ratios are EUR 31 721 and EUR 13 659, respectively. In addition, the results are sensitive to the time horizon and discontinuation rates. Conclusions: Our results indicate that infliximab therapy for patients with active AS should be cost-effective both in the societal perspective (dominating) and in the perspective of the health-care system (ranges from EUR 5300 to EUR 32 000 per QALY) in Spain.
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
- Olesen, J, et al.
(author)
-
Cost of disorders of the brain in Denmark
- 2008
-
In: Nordic journal of psychiatry. - : Informa UK Limited. - 1502-4725 .- 0803-9488. ; 62:2, s. 114-120
-
Journal article (peer-reviewed)
|
|
| 15. |
- Olesen, J, et al.
(author)
-
Funding of headache research in Europe
- 2007
-
In: Cephalalgia : an international journal of headache. - : SAGE Publications. - 0333-1024. ; 27:9, s. 995-999
-
Journal article (peer-reviewed)abstract
- Migraine costs European Society ¬27 billion per year. Other headaches may account for a similar amount. Given this enormous impact, the question arises as to whether the funding of research efforts in this field are sufficient. A recent European study called the Resource Allocation to Brain Research in Europe (RABRE) examined funding of brain research. Identified charities and Government agencies in Europe filled out a questionnaire regarding their funding of brain diseases. Industry spending was evaluated by three different previously validated methods. In the present report, detailed results are presented for migraine and other headaches. In 2004, migraine research was funded by nearly €315 million. Of this, €308 million was invested by the pharmaceutical industry, whereas public funding was estimated at €7 million. No funding was identified for non-migraine headache disorders. Of the public spending, €714 000 came from private foundations. There was a very large difference between different European countries in the funding of headache research. When public funding was compared with the cost of different brain disorders, migraine funding was in the middle range. This was due to relatively large industry funding. Compared with societal costs, migraine received the least public funds amongst all brain disorders, i.e. 0.025%. We conclude that migraine attracts reasonable interest from the pharmaceutical industry, but Governmental and charity funding is extremely low and no funding was identified for non-migraine headache disorders. Considering the huge economic impact of these disorders, public funding of research into migraine and other headaches should be greatly increased in the future.
|
|
| 16. |
|
|
| 17. |
- Pugliatti, M, et al.
(author)
-
Cost of disorders of the brain in Italy
- 2008
-
In: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. - : Springer Science and Business Media LLC. - 1590-1874. ; 29:2, s. 99-107
-
Journal article (peer-reviewed)
|
|
| 18. |
|
|
| 19. |
- Sillanpaa, M, et al.
(author)
-
Costs of brain disorders in Finland
- 2008
-
In: Acta neurologica Scandinavica. - : Hindawi Limited. - 1600-0404 .- 0001-6314. ; 117:3, s. 167-172
-
Journal article (peer-reviewed)
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
- Sobocki, P, et al.
(author)
-
Cost of depression in Europe
- 2006
-
In: The journal of mental health policy and economics. - 1091-4358. ; 9:2, s. 87-98
-
Journal article (peer-reviewed)
|
|
| 24. |
- Sobocki, P, et al.
(author)
-
Estimation of the cost of MS in Europe: extrapolations from a multinational cost study
- 2007
-
In: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 13:8, s. 1054-1064
-
Journal article (peer-reviewed)abstract
- The present study aims at estimating the total cost of MS in Europe based on actual cost data from nine countries and published epidemiological evidence. The epidemiological data are reported as 12 months prevalence estimates and cost data calculated as annual cost per patient at given levels of disease severity. Cost data are extrapolated to the rest of Europe based on a model, using economic indexes adjusting for price level differences in different sectors between countries. The aggregated annual cost estimates are presented in Euro for 2005. In 28 European countries with a population of 466 million, an estimated 380 000 individuals are affected by MS. The total annual cost of MS in Europe is estimated at 12.5 billion in year 2005, corresponding to a cost of 27 per European inhabitant. Direct costs represent slightly more than half of the total cost (6.0 billion). Informal care is estimated at 3.2 billion, and indirect costs due to morbidity at 3.2 billion. Thus, the largest component of costs is found outside the formal health care sector. Although our model appears to predict costs reasonably well, when comparing to previous national studies not included in the estimates, there are considerable uncertainties when extrapolating cost data across countries even within Europe. These weaknesses can only be overcome by collecting primary data. Multiple Sclerosis 2007; 13: 1054—1064. http://msj.sagepub.com
|
|
| 25. |
|
|
